Pipendoxifene: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|A selective estrogen receptor modulator}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| IUPAC_name = 1-[4-[(1Z)-2-(4-hydroxyphenyl)-3-(4-piperidin-1-ylbutoxy)phenyl]phenyl]ethanone | |||
| image = Pipendoxifene_skeletal.svg | |||
| image_size = 250px | |||
| image_alt = Skeletal structure of Pipendoxifene | |||
}} | |||
'''Pipendoxifene''' is a [[selective estrogen receptor modulator]] (SERM) that has been studied for its potential use in the treatment of [[breast cancer]] and other estrogen-related conditions. It is known for its ability to act as an [[estrogen receptor]] antagonist in breast tissue while potentially acting as an agonist in other tissues such as bone. | |||
Pipendoxifene | ==Mechanism of Action== | ||
Pipendoxifene functions by binding to [[estrogen receptors]] in various tissues. As a SERM, it exhibits tissue-selective activities, meaning it can block or activate estrogen receptors depending on the tissue type. In breast tissue, pipendoxifene acts as an antagonist, inhibiting the proliferative action of estrogen, which is beneficial in the treatment of estrogen receptor-positive breast cancer. In bone tissue, it may act as an agonist, helping to maintain bone density and reduce the risk of [[osteoporosis]]. | |||
== | ==Pharmacokinetics== | ||
The pharmacokinetic profile of pipendoxifene involves its absorption, distribution, metabolism, and excretion. It is typically administered orally, and its bioavailability can be influenced by factors such as food intake and individual metabolic differences. The drug is metabolized primarily in the liver and excreted through the kidneys. | |||
Pipendoxifene | ==Clinical Applications== | ||
Pipendoxifene has been investigated for its potential use in the treatment of [[breast cancer]], particularly in postmenopausal women. Its ability to selectively modulate estrogen receptors makes it a candidate for reducing the risk of breast cancer recurrence. Additionally, its effects on bone density suggest potential use in the prevention of osteoporosis in postmenopausal women. | |||
== Side Effects == | ==Side Effects== | ||
As with other SERMs, pipendoxifene may have side effects, including hot flashes, leg cramps, and an increased risk of venous thromboembolism. The risk-benefit profile must be carefully considered in patients with a history of thromboembolic events. | |||
==Research and Development== | |||
Research on pipendoxifene is ongoing, with studies focusing on its efficacy and safety in various populations. Clinical trials are essential to determine its long-term effects and potential as a therapeutic agent in estrogen-related conditions. | |||
==Related pages== | |||
* [[Selective estrogen receptor modulator]] | * [[Selective estrogen receptor modulator]] | ||
* [[Breast cancer]] | * [[Breast cancer]] | ||
* [[Estrogen receptor]] | * [[Estrogen receptor]] | ||
* [[ | * [[Osteoporosis]] | ||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
[[Category:Breast cancer | [[Category:Breast cancer treatment]] | ||
Revision as of 12:09, 15 February 2025
A selective estrogen receptor modulator
| Pipendoxifene | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Pipendoxifene is a selective estrogen receptor modulator (SERM) that has been studied for its potential use in the treatment of breast cancer and other estrogen-related conditions. It is known for its ability to act as an estrogen receptor antagonist in breast tissue while potentially acting as an agonist in other tissues such as bone.
Mechanism of Action
Pipendoxifene functions by binding to estrogen receptors in various tissues. As a SERM, it exhibits tissue-selective activities, meaning it can block or activate estrogen receptors depending on the tissue type. In breast tissue, pipendoxifene acts as an antagonist, inhibiting the proliferative action of estrogen, which is beneficial in the treatment of estrogen receptor-positive breast cancer. In bone tissue, it may act as an agonist, helping to maintain bone density and reduce the risk of osteoporosis.
Pharmacokinetics
The pharmacokinetic profile of pipendoxifene involves its absorption, distribution, metabolism, and excretion. It is typically administered orally, and its bioavailability can be influenced by factors such as food intake and individual metabolic differences. The drug is metabolized primarily in the liver and excreted through the kidneys.
Clinical Applications
Pipendoxifene has been investigated for its potential use in the treatment of breast cancer, particularly in postmenopausal women. Its ability to selectively modulate estrogen receptors makes it a candidate for reducing the risk of breast cancer recurrence. Additionally, its effects on bone density suggest potential use in the prevention of osteoporosis in postmenopausal women.
Side Effects
As with other SERMs, pipendoxifene may have side effects, including hot flashes, leg cramps, and an increased risk of venous thromboembolism. The risk-benefit profile must be carefully considered in patients with a history of thromboembolic events.
Research and Development
Research on pipendoxifene is ongoing, with studies focusing on its efficacy and safety in various populations. Clinical trials are essential to determine its long-term effects and potential as a therapeutic agent in estrogen-related conditions.
